Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and
pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular …

Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-
myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and …

Immunomodulatory agents (IMiD's) have become an important drug category in the
treatment of multiple myeloma. The agents have a complex mechanism of action that …

Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable
using the currently available treatments. Cytogenetic, molecular and proteonomic …

Although several mechanisms have been proposed to explain the activity of thalidomide,
lenalidomide and pomalidomide in multiple myeloma (MM), including demonstrable anti …

The introduction of novel drugs (thalidomide, lenalidomide [immunomodulatory drugs;
IMiDs] and bortezomib) optimistically changed the outcome of patients with multiple …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Growth and survival of multiple myeloma (MM) cells depend on intrinsic, cell-autonomous
parameters, such as the genetic lesions harboured by the MM cells, as well as extracellular …

Immunomodulatory drugs (IMiDs) are thalidomide analogues that retain the direct anticancer
cytotoxic and immunological activity of their parent compound, but with a different toxicity …

Multiple myeloma is the second most common hematological cancer in the world. It is
characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic …